WHO-Recommended Antibiotics Ineffective for Many Neonatal Sepsis Cases

Why It Matters

The findings expose a critical gap in neonatal sepsis treatment in LMICs, where ineffective empirical antibiotics contribute to higher mortality and highlight the urgent need for locally tailored antimicrobial strategies.

Key Takeaways

• WHO's ampicillin‑gentamicin covers only 25% of pathogens in LMICs
• Empirical therapy mismatch doubled neonatal mortality in unadjusted analysis
• Only 40 of 14,259 neonates received WHO‑recommended regimen
• Local resistance patterns vary across Pakistan, Bangladesh, Nigeria
• Tailored antibiotic guidelines and AMR surveillance essential for newborn survival

Pulse Analysis

Neonatal sepsis remains a leading cause of infant death worldwide, yet the World Health Organization’s first‑line recommendation—ampicillin plus gentamicin—was derived from data in high‑income hospitals. The BARNARDS II study, spanning 13 tertiary units across Pakistan, Bangladesh and Nigeria, evaluated 14,259 newborns treated empirically for suspected sepsis between February 2024 and October 2025. By focusing on culture‑confirmed cases with susceptibility results, the researchers uncovered that the WHO regimen would have been active against merely a quarter of the identified pathogens, a stark contrast to its presumed broad efficacy.

The study’s mortality analysis further emphasizes the stakes. While 36.8 % of neonates received at least one effective drug, the remaining 63.2 % faced inappropriate therapy, which correlated with a two‑fold increase in raw mortality (32.1 % versus 17.9 %). Although adjustment for gestational age attenuated this relationship, the data reveal that antimicrobial resistance, not just patient fragility, drives poor outcomes. Moreover, the research highlighted considerable heterogeneity: amikacin plus cefotaxime was the most common regimen, and only 40 infants actually received the WHO‑recommended combination, reflecting clinicians’ pragmatic deviation from guidelines in the face of local resistance data.

These insights compel a shift from one‑size‑fits‑all protocols toward region‑specific antibiotic policies. Strengthening laboratory capacity for rapid pathogen identification, expanding AMR surveillance networks, and integrating stewardship programs are essential steps to align empirical choices with prevailing resistance patterns. Policymakers and global health donors must invest in sustainable access to effective drugs and diagnostic tools, ensuring that newborns in low‑resource settings receive the right treatment at the right time, ultimately reducing preventable mortality.